Swissmedic Approves Durvalumab for Perioperative Treatment of Resectable NSCLC

Thursday, 4 July 2024 | Lung Cancer

Durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, has received approval from Swissmedic for the treatment of adult patients with resectable NSCLC (tumours ≥4 cm and/or positive lymph node involvement) without known mutations of the epidermal growth factor receptor (EGFR) or rearrangements of anaplastic lymphoma kinase (ALK).

To continue, please login or sign up first